教育及工作经历
2013-2018 北京大学，生物医学前沿创新中心(BIOPIC)，博士
2018-2024 清华大学，免疫学研究所，博士后
2024-2025 上海市免疫治疗创新研究院，助理研究员
2025至今 上海交通大学药学院，课题组长(PI)、长聘教轨副教授、博士生导师
郭心怡博士迄今以第一作者(含共同)在Cell, Nature Medicine, Cancer Cell等学术期刊发表多篇高水平学术论文，总被引次数超过4700次。主持国自然青年项目、中国博士后面上项目各一项，获中国授权专利4项。
荣誉及奖励
2021 北京市科学技术奖-自然科学奖一等奖
2019 清华-北大生命科学联合中心CLS博士后基金(特等)
2018 国家博士后支持计划
2018 北京市优秀毕业生
2018 北京大学优秀毕业论文
2017 中国生命科学十大进展
2017 中国十大医学科技新闻
2017 Cell出版社中国年度论文
Dr. Xinyi Guo received her Ph.D. degree from Peking University, Biomedical Pioneering Innovation Center (BIOPIC) in 2018, and was recognized as an Outstanding Graduate of Beijing. She subsequently pursued postdoctoral research at the Institute for Immunology, Tsinghua University, supported by the National Postdoctoral Fellowship Program and Tsinghua University Outstanding Postdoctoral Fellowship. Dr. Guo joined the School of Pharmaceutical Sciences at Shanghai Jiao Tong University as an independent PI in 2025. Her work has been published in several high-impact journals including Cell, Nature Medicine, and Cancer Cell, with total citations exceeding 4,700.
本课题组诚聘免疫学、生物信息学方向的博士后，同时欢迎对免疫学和单细胞多组学感兴趣的本科生、硕士生和博士生加入实验室！
Recruiting postdoctoral researchers in the fields of immunology and bioinformatics. Welcome to join us!
本课题组长期致力于肿瘤免疫领域，结合单细胞多组学与动物模型开展疾病相关研究：
1. 癌症免疫治疗中响应与耐药的免疫机制；
2. 抗原特异性T细胞在癌症、感染、自免等疾病中的应答；
3. 治疗性靶点挖掘与新型免疫疗法开发。
Research Area:
The Guo Lab integrates single-cell multi-omics and animal models to address key questions in human diseases, with a particular focus on:
1. Immune mechanisms underlying response and resistance to cancer immunotherapy;
2. Antigen-specific T cell responses in cancer, infection, and autoimmune diseases;
3. Identification of therapeutic targets and development of novel immunotherapies.
1. X. Guo*, H. Nie*, W. Zhang*, J. Li, J. Ge, …, & C. Dong. Contrasting cytotoxic and regulatory T cell responses associated with distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell (2025), 43: 1-21.
2. K. Wei, R. Li, X. Zhao, …, X. Guo, …, & C. Dong. TRIM28 is an essential regulator of three-dimensional chromatin state underpinning CD8+ T cell activation. Nature Communications (2025), 16: 750.
3. X. Bai, S. Chen, X. Chi, B. Xie, X. Guo, …, & C. Dong. Reciprocal regulation of T follicular helper cells and dendritic cells drives colitis development. Nature Immunology (2024), 25: 1383–1394.
4. Q. Sun, D. Cai, D. Liu , …, & X. Guo, …, & C. Dong. BCL6 promotes a stem-like CD8+ T cell program in cancer via antagonizing BLIMP1. Science Immunology (2023), 8: eadh1306.
5. X. Guo and C. Dong. Zooming on T cells in cancer. Science China Life Sciences (2022), 65: 1466-1468.
6. L. Zhang*, X. Yu*, L. Zheng*, …, & X. Guo, …, & Z. Zhang. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature (2018), 564: 268-272.
7. X. Guo*, Y. Zhang*, L. Zheng *, C. Zheng *, J. Song *, …, & Z. Zhang. Global characterization of infiltrating T cells in non-small cell lung cancer. Nature Medicine (2018), 24: 978-985.
8. C. Zheng*, L. Zheng*, J. Yoo*, H. Guo*, Y. Zhang*, X. Guo*, …, & Z. Zhang. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell (2017), 169: 1342–1356.
